Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.

@article{Baselga2002CombinedAR,
  title={Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.},
  author={Juan Baselga},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2002},
  volume={13 1},
  pages={
          8-9
        }
}
  • Juan Baselga
  • Published 2002 in
    Annals of oncology : official journal of the…
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2006

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

Annals of oncology : official journal of the European Society for Medical Oncology • 2002
View 1 Excerpt

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2002

Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)

L Saltz, M Rubin, H Hochster
Proc Am Soc Clin Oncol • 2001

Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells

J Anido, J Albanell, F Rojo
Proc Am Soc Clin Oncol • 2001
View 2 Excerpts

Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (IRESSA) inhibits HER2/ Neu (erb-2) overexpressing breast tumor cells

SL Moulder, M Yakes, R Bianco, C. Arteaga
Proc Am Soc Clin Oncol • 2001
View 1 Excerpt

Targeting the epidermal growth factor receptor: a clinical reality.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2001
View 2 Excerpts

Untangling the ErbB signalling network

Nature Reviews Molecular Cell Biology • 2001
View 2 Excerpts

Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck carcinoma

J Bonner, MP Ezekiel, F Robert
Proc Am Soc Clin Oncol • 2000

Similar Papers

Loading similar papers…